Jazz Pharmaceuticals plc
JAZZ
Positions held
Your positionsJAZZ isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Jazz Pharmaceuticals has a strong competitive position in the biotechnology sector, with a focus on innovative therapies that address unmet medical needs.
- The company reported a revenue increase of 13% compared to the prior quarter, reaching $1.2 billion.
- Jazz's gross margin improved to 90.4%, up from 87.5% in the previous quarter.
- The overall market sentiment is bearish, with a strong sell signal indicating potential challenges ahead for Jazz Pharmaceuticals.
- The operating margin compressed to 26.9%, which may raise concerns about profitability.
- Jazz's net income for the year 2025 was negative at -$356.148 million, highlighting financial difficulties.
Fundamentals
| Market cap | $14.44B | Enterprise value | $16.65B | Trailing P/E | 15.25 | Forward P/E | 8.59 |
| PEG | 0.96 | Price / book | 3.00 | Beta | 0.37 | Dividend yield | 0.00% |
| Revenue growth | 15.5% | Earnings growth | — | Gross margin | 91.4% | Operating margin | 26.9% |
| Profit margin | 20.4% | ROE | 22.1% | ROA | 6.9% | Debt / equity | 0.92 |
| Current ratio | 1.78 | Free cash flow | $1.43B | Analyst recommendation | strong_buy | Mean target | $294.36 |
| 52w high | $266.38 | 52w low | $128.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $1.2B | $1.1B | $1.0B | — |
| Op margin | 26.9% | 31.5% | 21.2% | 8.9% | 20.9% | — |
| Net income | $193M | $293M | $203M | $251M | -$719M | — |
| Gross margin | 90.4% | 87.5% | 87.2% | 88.6% | 88.9% | — |
| Gross profit | $1.1B | $935M | $1.0B | $997M | $929M | — |
| Operating income | $325M | $337M | $255M | $100M | $219M | — |
- Revenue +13% vs prior quarter ($1.2B vs $1.1B).
- Gross margin 90.4% (was 87.5% prior quarter).
- Operating margin compressed to 26.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.1B | $3.8B | $3.7B | — |
| Op margin | 12.1% | 17.9% | 15.6% | 14.0% | — |
| Net income | -$356M | $560M | $415M | -$224M | — |
| Gross margin | 88.2% | 89.0% | 88.6% | 85.2% | — |
| Gross profit | $3.8B | $3.6B | $3.4B | $3.1B | — |
| Operating income | $518M | $727M | $598M | $512M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Trims Price Target on Jazz Pharmaceuticals to $296 From $299, Keeps Outperform Rating
2026-10-05 · Jazz Pharmaceuticals Insider Sold Shares Worth $1,381,980, According to a Recent SEC Filing
2026-09-30 · Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
2026-09-30 · Target upgraded, Moderna downgraded: Wall Street's top analyst calls
2026-09-30 · Citigroup Initiates Jazz Pharmaceuticals at Buy With $325 Price Target
2026-09-22 · ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
2026-09-20 · Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
2026-09-20 · Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
2026-09-18 · Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
2026-09-18 · Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet
2026-09-15 · Jazz Pharmaceuticals Completes $820 Million Upfront Acquisition of Actio Biosciences
Price (daily)
Full chart · RSI · MACD · patterns